AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26450424 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia in uncontrolled diabetes mellitus (HbA1c > 7 %)
Number of subjects: 66
Study 26450424 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 26451031 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative location model for ICH engagement
Number of subjects: 111
Study 26451310 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous or donor-derived T cells expressing CD19 chimeric antigen receptors (CARs) with 4-1BB and CD3ζ moiety
Number of subjects: 9
Study 26451310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Number of subjects: 9
Study 26451310 — intervention group
Group type: EXPERIMENTAL
Intervention: No conditioning chemotherapy
Number of subjects: 9
Study 26451310 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived anti-CD19 CART cells
Number of subjects: 9
Study 26452027 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA sequencing using a 54-gene panel
Number of subjects: 75
Study 26452027 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis during cetuximab-based treatment
Number of subjects: 75
Study 26452027 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis during cetuximab/irinotecan chemotherapy
Number of subjects: 75
Study 26452346 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP score variability (standard deviation of four GEP scores collected ≥315 days post-transplantation)
Number of subjects: 737
Study 26452346 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP score variability
Number of subjects: 737
Study 26452397 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of herpes zoster vaccine (ZV) administered to participants aged ≥ 70 years.
Number of subjects: 200
Study 26452397 — intervention group
Group type: COMPARATOR
Intervention: First dose of herpes zoster vaccine (ZV) administered to age-matched groups (100 participants aged 50-59 years, 100 aged 60-69 years, and 200 aged ≥ 70 years).
Number of subjects: 200
Study 26452405 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day tailored therapy based on H. pylori culture and MIC test
Number of subjects: 219
Study 26452405 — intervention group
Group type: COMPARATOR
Intervention: 14-day EBMT therapy
Number of subjects: 219
Study 26452405 — intervention group
Group type: COMPARATOR
Intervention: 14-day MEA therapy
Number of subjects: 219
Study 26452447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-daily
Number of subjects: 958
Study 26452447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 958
Study 26452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB) monitored using acceleromyography, rNMB defined as a train-of-four (TOF) ratio <0.9
Number of subjects: 1571
Study 26452561 — intervention group
Group type: EXPERIMENTAL
Intervention: NMB reversed with neostigmine in 78% of patients
Number of subjects: 1571
Study 26452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <45 years
Number of subjects: 1571
Study 26452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of one neuromuscular blocking agent (NMBA)
Number of subjects: 1571
Study 26452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from neostigmine administration to endotracheal extubation ≥10 min
Number of subjects: 1571
Study 26452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from last NMBA administration to endotracheal extubation ≥60 min
Number of subjects: 1571
Study 26453446 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz deep rTMS (1200 pulses) over the mPFC, followed by nine additional sessions of daily rTMS
Number of subjects: 20
Study 26453446 — intervention group
Group type: COMPARATOR
Intervention: Control group (aged-matched healthy controls)
Number of subjects: 20
Study 26453479 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips fluid accumulation vest (FAV) used for daily monitoring of transthoracic bioimpedance for 45 days post-discharge.
Number of subjects: 180
Study 26453479 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips fluid accumulation vest (FAV) monitoring.
Number of subjects: 180
Study 26453592 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP/START criteria applied to health administrative data (HAD)
Number of subjects: 275
Study 26453592 — intervention group
Group type: EXPERIMENTAL
Intervention: Beers criteria applied to health administrative data (HAD)
Number of subjects: 275
Study 26453687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapien 3 THV
Number of subjects: 598
Study 26453687 — intervention group
Group type: COMPARATOR
Intervention: Sapien XT THV
Number of subjects: 598
Study 26453688 — intervention group
Group type: EXPERIMENTAL
Intervention: ST elevation or presumably new left bundle branch block
Number of subjects: 210
Study 26453688 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ECG signs indicating myocardial ischemia
Number of subjects: 210
Study 26453688 — intervention group
Group type: EXPERIMENTAL
Intervention: No ECG signs indicating myocardial ischemia
Number of subjects: 210
Study 26453688 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ECG findings
Number of subjects: 210
Study 26453688 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial nonshockable rhythms
Number of subjects: 210
Study 26453688 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-months survival with good neurological outcome
Number of subjects: 210
Study 26453983 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone on hCG day (mean ± SD: 1.13 ± 0.69 ng/mL) among agonist-treated patients
Number of subjects: 0
Study 26453983 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone on hCG day (mean ± SD: 1.11 ± 0.58 ng/mL) among recombinant FSH stimulation
Number of subjects: 0
Study 26453983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy rate
Number of subjects: 0
Study 26453983 — intervention group
Group type: COMPARATOR
Intervention: P-hCG value
Number of subjects: 0
Study 26454362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay, concentrations less than 5 ng/L
Number of subjects: 6304
Study 26454362 — intervention group
Group type: COMPARATOR
Intervention: Troponin concentration of 5 ng/L or more
Number of subjects: 6304
Study 26454612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-Dense Paclitaxel, Trastuzumab, and Lapatinib (PTL)
Number of subjects: 20
Study 26454620 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (30 mg/m² on days 1 and 8 every 21 days)
Number of subjects: 31
Study 26454620 — intervention group
Group type: COMPARATOR
Intervention: Subsequent platinum-based chemotherapy (58% of patients)
Number of subjects: 31
Study 26455862 — intervention group
Group type: EXPERIMENTAL
Intervention: OSNA (One step nucleic acid amplification) using CK19 mRNA concentration
Number of subjects: 55
Study 26455862 — intervention group
Group type: COMPARATOR
Intervention: Histopathological analysis
Number of subjects: 55
Study 26455870 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemic episodes
Number of subjects: 5783
Study 26455870 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemic episodes
Number of subjects: 5783
Study 26455870 — intervention group
Group type: EXPERIMENTAL
Intervention: Any hypoglycaemic episode
Number of subjects: 5783
Study 26455870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 5783
Study 26455892 — intervention group
Group type: EXPERIMENTAL
Intervention: Toddlers of GG mothers at the FADS2 rs174575 SNP
Number of subjects: 71
Study 26455892 — intervention group
Group type: EXPERIMENTAL
Intervention: Toddler methylation status
Number of subjects: 71
Study 26455892 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal methylation status
Number of subjects: 71
Study 26456229 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy followed by endometrial biopsy for diagnosis of chronic endometritis (CE).
Number of subjects: 99
Study 26456229 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy for diagnosis of CE.
Number of subjects: 99
Study 26456677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Number of subjects: 14
Study 26457029 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Eye Panoramic cap
Number of subjects: 33
Study 26457065 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural micronized progesterone vaginal tablet (FE 999913) administered twice daily
Number of subjects: 108
Study 26457065 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study 26457225 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic drugs perception assessment
Number of subjects: 908
Study 26457225 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic gain perception
Number of subjects: 908
Study 26457225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacovigilance mandates perception
Number of subjects: 908
Study 26457225 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of scores by location and specialty
Number of subjects: 908
Study 26457568 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g daily for 8 weeks)
Number of subjects: 14
Study 26458184 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM symptoms (e.g., sad mood)
Number of subjects: 3463
Study 26458184 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-DSM symptoms (e.g., anxiety)
Number of subjects: 3463
Study 26458184 — intervention group
Group type: EXPERIMENTAL
Intervention: Network perspective
Number of subjects: 3463
Study 26458184 — intervention group
Group type: EXPERIMENTAL
Intervention: Central symptoms research
Number of subjects: 3463
Study 26458411 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI use at the time of coronary intervention
Number of subjects: 8582
Study 26458411 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge PPI use
Number of subjects: 8582
Study 26458788 — intervention group
Group type: EXPERIMENTAL
Intervention: Manchester Triage System (MTS) implemented by triage nurses upon arrival in the ED.
Number of subjects: 2407
Study 26458804 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg DEN1-80E with 1.25 mg of elemental aluminum
Number of subjects: 0
Study 26458804 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg DEN1-80E with 1.25 mg of elemental aluminum
Number of subjects: 0
Study 26458809 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nurse-delivered, publicly funded rotavirus vaccination program
Number of subjects: 722
Study 26458809 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered program
Number of subjects: 722
Study 26458809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination program)
Number of subjects: 722
Study 26458809 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health-delivered vaccination program
Number of subjects: 722
Study 26458809 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal rotavirus vaccination program
Number of subjects: 722
Study 26459220 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C Pittsburgh compound B (PIB) PET scan to quantify global amyloid deposition
Number of subjects: 22
Study 26459220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical multiple linear regression analysis controlling for age, education, and ApoE ε4 status
Number of subjects: 22
Study 26459321 — intervention group
Group type: EXPERIMENTAL
Intervention: Food responsiveness at 3 months
Number of subjects: 210
Study 26459321 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowness in eating and satiety responsiveness at 3 months
Number of subjects: 210
Study 26459321 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetitive traits at 12 months
Number of subjects: 210
Study 26459405 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine and novel cardiovascular, inflammatory and renal biomarkers assessment
Number of subjects: 0
Study 26459405 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up through telephone calls and questionnaires
Number of subjects: 0
Study 26459405 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cardiovascular assessment through clinical exam, instrumental tests (electrocardiogram, echocardiogram), and biological parameters
Number of subjects: 0
Study 26459405 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological collection on plasma and urine
Number of subjects: 0
Study 26459405 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification of ICU survivors
Number of subjects: 0
Study 26459812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (VEGF blockage)
Number of subjects: 0
Study 26459812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (Integrin inhibition)
Number of subjects: 0
Study 26459812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib or Cediranib (VEGF receptor inhibition)
Number of subjects: 0
Study 26459812 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib or Dasatinib (PDGFR inhibition)
Number of subjects: 0
Study 26459812 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (Protein kinase C inhibition)
Number of subjects: 0
Study 26459812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus, Everolimus, or Temsirolimus (mTOR inhibition)
Number of subjects: 0
Study 26459932 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention and renal angiography
Number of subjects: 181
Study 26459932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models
Number of subjects: 181
Study 26459996 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) formula
Number of subjects: 80
Study 26459996 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett True-K formula (True-K)
Number of subjects: 80
Study 26459996 — intervention group
Group type: COMPARATOR
Intervention: Wang-Koch-Maloney (WKM) formula
Number of subjects: 80
Study 26459996 — intervention group
Group type: COMPARATOR
Intervention: Shammas formula
Number of subjects: 80
Study 26459996 — intervention group
Group type: COMPARATOR
Intervention: Haigis-L formula
Number of subjects: 80
Study 26459996 — intervention group
Group type: COMPARATOR
Intervention: Average of the five formulas
Number of subjects: 80
Study 26460303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg orally twice a day)
Number of subjects: 21
Study 26460303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 21
Study 26462280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue breakfast (LRB)
Number of subjects: 214
Study 26462280 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids alone (CFD)
Number of subjects: 214
Study 26462968 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongest Families FASD intervention
Number of subjects: 200
Study 26462968 — intervention group
Group type: COMPARATOR
Intervention: Control group (static resource Web page)
Number of subjects: 200
Study 26464110 — intervention group
Group type: EXPERIMENTAL
Intervention: Peace of Mind Program (PMP)
Number of subjects: 0
Study 26464110 — intervention group
Group type: COMPARATOR
Intervention: Control (self as control)
Number of subjects: 0
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line NIV for ARF
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ICU NIV
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-extubation NIV
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line NIV in acute-on-chronic RF
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line NIV in cardiogenic pulmonary edema
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line NIV in de novo ARF
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV success rate
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV failure in de novo ARF
Number of subjects: 4132
Study 26464393 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 4132
Study 26464429 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic outcome adjudication module
Number of subjects: 7336
Study 26464429 — intervention group
Group type: COMPARATOR
Intervention: Three-step adjudication procedure
Number of subjects: 7336
Study 26464429 — intervention group
Group type: COMPARATOR
Intervention: Six-step adjudication procedure
Number of subjects: 7336
Study 26464715 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3-positive tumors
Number of subjects: 156
Study 26464715 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME-positive tumors
Number of subjects: 156
Study 26464715 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one antigen positive
Number of subjects: 156
Study 26464715 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of tumor antigen mRNA expression
Number of subjects: 156
Study 26464803 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 54
Study 26465217 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher child-reported maternal warmth in early adolescence
Number of subjects: 240
Study 26465217 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher child-reported maternal warmth in late adolescence
Number of subjects: 240
Study 26465217 — intervention group
Group type: COMPARATOR
Intervention: Mother-reported warmth in early adolescence
Number of subjects: 240
Study 26465217 — intervention group
Group type: COMPARATOR
Intervention: Mother-reported warmth in late adolescence
Number of subjects: 240
Study 26465376 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaires
Number of subjects: 2566
Study 26465376 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultation
Number of subjects: 2566
Study 26465376 — intervention group
Group type: COMPARATOR
Intervention: E-mail consultation
Number of subjects: 2566
Study 26465376 — intervention group
Group type: COMPARATOR
Intervention: Age-related preference for e-mail
Number of subjects: 2566
Study 26465376 — intervention group
Group type: COMPARATOR
Intervention: Gender-related preference
Number of subjects: 2566
Study 26465392 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA women with typical LPDFs
Number of subjects: 30
Study 26465392 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA women with atypical LPDFs
Number of subjects: 30
Study 26465780 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg orally, once daily for 28 days
Number of subjects: 24
Study 26465780 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg on Day 28
Number of subjects: 24
Study 26465780 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Number of subjects: 24
Study 26466143 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-barcode-based immune repertoire sequencing assay
Number of subjects: 12
Study 26466328 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 μg)
Number of subjects: 305
Study 26466328 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 305
Study 26466682 — intervention group
Group type: EXPERIMENTAL
Intervention: p-STAT6 and PU.1 expression in Th9 cells; NF-κB expression in eosinophils; serum IL-9 and IL-5 levels.
Number of subjects: 19
Study 26466682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial allergen challenge.
Number of subjects: 19
Study 26466682 — intervention group
Group type: COMPARATOR
Intervention: Eosinophil apoptosis.
Number of subjects: 19
Study 26466682 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis in AA group.
Number of subjects: 19
Study 26466682 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MFI of NF-κB and eosinophil apoptosis.
Number of subjects: 19
Study 26467105 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA)
Number of subjects: 391
Study 26467105 — intervention group
Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT-MPI)
Number of subjects: 391
Study 26467455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Number of subjects: 504
Study 26467455 — intervention group
Group type: COMPARATOR
Intervention: DTC-negative BM
Number of subjects: 504
Study 26467455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate application
Number of subjects: 504
Study 26467555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquitin C-terminal hydrolase-L1 (UCH-L1) measured within 6 hours of injury
Number of subjects: 251
Study 26467555 — intervention group
Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein (GFAP) measured within 6 hours of injury
Number of subjects: 251
Study 26467555 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B measured within 6 hours of injury
Number of subjects: 251
Study 26467555 — intervention group
Group type: EXPERIMENTAL
Intervention: All three biomarkers (GFAP, UCH-L1, S100B)
Number of subjects: 251
Study 26467555 — intervention group
Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 251
Study 26467644 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 6.5%
Number of subjects: 1128
Study 26467644 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c threshold of 6.3%
Number of subjects: 1128
Study 26467644 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 5.6%
Number of subjects: 1128
Study 26467644 — intervention group
Group type: COMPARATOR
Intervention: OGTT
Number of subjects: 1128
Study 26468043 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologically confirmed pertussis infection (anti-PT IgG titre ⩾62·5 IU/ml)
Number of subjects: 312
Study 26468043 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of cough, paroxysms, breathlessness/chest pain
Number of subjects: 312
Study 26468043 — intervention group
Group type: EXPERIMENTAL
Intervention: Median total direct medical cost per pertussis episode
Number of subjects: 312
Study 26468043 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D index score of cases
Number of subjects: 312
Study 26468228 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of PD-L1
Number of subjects: 305